

A

Somatic mutation & heterozygous
SNP-based tumor content
estimated for 626 samples.

Group 1

n = 273

Mutation-based estimation is used.

Somatic mutation used is in $\geq 75\%$ of same-patient samples.

Group 2

n = 164

SNP estimation is used.

Somatic mutation used is in $< 75\%$ of same-patient samples.

Group 3

n = 188

Mutation-based estimation is used.

SNP-based estimation is not feasible due to low TC or no SNPs in regions of copy loss.

134 samples had no detectable tumor with any method

B